Researchers have developed new AI approach to select chemical compounds potentially effective for treating tuburculosis.
PROTACs have helped redefine what may be possible in drug discovery. By harnessing the ubiquitin-proteasome system to ...
The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...
Researchers from University of Arizona present a new therapeutic target to shield nerve cells from the damage of ALS.
This eBook explores how researchers can move beyond correlation and towards mechanism in microbiome research—from preserving physiologically relevant microbial communities to directly measuring ...
Less than a month after its stock roller-coastered on safety signals associated with its late-stage ulcerative colitis (UC) ...
Synthetic organizers provide a way to control formation of kidney organoids as more reliable models for studying disease and ...
As instruments grow faster, leaders say clinical impact will depend on trust, standards, data, and assays built for real ...
To date, the company has raised over $34 million from investors and operates a 15-person team at facilities at Johns Hopkins Medical Campus.
Researchers identified VIP inhibitory neurons in Huntington’s disease and used optogenetics to restore motor neuron activity in mice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results